Illumina, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended July 1, 2012, compared with July 3, 2011. Both periods comprised 13 and 26 weeks, respectively. Illumina develops and sells genetic analysis systems, instruments, consumables, software, and related services serving sequencing, genotyping, gene expression, molecular diagnostics, and research markets.
Financial performance and position
| Metric | Q2 2012 | Q2 2011 | First half 2012 | First half 2011 |
|---|---|---|---|---|
| Revenue | $280.6 million | $287.5 million | $553.4 million | $570.0 million |
| Gross profit | $193.0 million | $193.4 million | $374.0 million | $381.4 million |
| Gross margin | 68.8% | 67.3% | 67.6% | 66.9% |
| Income from operations | $43.0 million | $66.0 million | $92.6 million | $135.4 million |
| Net income | $23.4 million | $30.6 million | $49.6 million | $54.8 million |
| Diluted EPS | $0.18 | $0.22 | $0.37 | $0.37 |
| Cash flow from operations | Not separately provided | Not separately provided | $161.8 million | $159.8 million |
- Q2 product revenue declined 4% to $258.8 million; service and other revenue increased 24% to $21.8 million.
- Consumables revenue increased 16% to $183.7 million in Q2, while instrument revenue declined 32% to $72.2 million. The shift toward higher-margin consumables supported gross-margin expansion.
- Operating expenses increased 18% in Q2 and 14% year to date, primarily due to a $21.4 million in-process research and development impairment, $14.8 million of year-to-date Roche tender-offer costs, and restructuring charges.
- Cash, cash equivalents, and short-term investments totaled approximately $1.3 billion at July 1, 2012, including $316.4 million of cash and cash equivalents and $985.3 million of short-term investments.
- Total debt carrying value was $824.7 million, consisting primarily of $789.0 million of 0.25% convertible notes due 2016 and $35.7 million of 0.625% convertible notes due 2014 classified as current. The 2014 notes had $40.1 million of principal outstanding.
- Total assets were $2.35 billion and stockholders’ equity was $1.18 billion at July 1, 2012.
- The company repurchased approximately 795,000 shares for $32.5 million during the first half under a $250 million authorization; $217.5 million remained available at quarter-end.
Material changes versus the prior comparable period
- First-half revenue decreased 2.9%, reflecting a 31% decline in instrument revenue that more than offset 16% growth in consumables revenue and 17% growth in service and other revenue.
- First-half operating income decreased 31.6%, principally because of higher research and development spending, the IPR&D impairment, tender-offer expenses, and restructuring costs.
- First-half net income declined 9.4%, while diluted EPS remained $0.37 because the prior-year period had substantially greater dilution from convertible notes, equity awards, and warrants.
- Other expense improved materially because the first half of 2011 included a $36.9 million loss on extinguishment of debt; 2012 other expense primarily reflected foreign-exchange losses.
- Operating cash flow increased approximately 1% despite lower net income, supported by non-cash charges including share-based compensation, debt-discount accretion, deferred taxes, and the IPR&D impairment.
Outlook, risks, contingencies, and unusual items
- Management expected full commercial shipments of the HiSeq 2500 to begin in the second half of 2012 and anticipated continued sequencing-consumable growth from a larger installed base and higher consumable revenue per HiSeq system.
- Management expected uncertainty in U.S. and European government and academic research funding to continue through the second half of 2012 and into 2013. Approximately one-third of total revenue was estimated to be derived directly or indirectly from NIH funding.
- Management stated that existing cash, investments, and operating cash flow were expected to fund operating needs for at least the next 12 months, absent unforeseen circumstances. No material capital-expenditure commitments were identified.
- Roche’s unsolicited tender offer, initially at $44.50 per share and later revised to $51.00, expired on April 20, 2012. Illumina recorded $14.8 million of related expenses in the first half and maintained a shareholder-rights plan expiring January 26, 2017.
- The company recorded a $21.4 million IPR&D impairment after resources were redirected and no near-term additional investment was planned. Goodwill testing in the second quarter resulted in no impairment.
- Legal matters included a settled patent-infringement case, shareholder litigation related to the Roche offer, and other ordinary-course claims. Legal contingency accruals increased by $3.0 million in the first half; management could not estimate the ultimate loss for other pending matters but did not expect an aggregate material adverse effect.
- Additional restructuring and headquarters-relocation expenses were expected during 2012. Estimated total restructuring costs were $13.9 million, with $648,000 accrued at July 1, 2012.
- The filing reported no material changes in risk factors, no significant off-balance-sheet arrangements, and effective disclosure controls and procedures.
Investor verification points
- Verify whether consumables growth and HiSeq 2500 commercialization offset continued instrument-revenue pressure.
- Track government and academic funding, particularly NIH funding and potential sequestration effects on customer purchasing.
- Assess the sustainability of the 67.6% first-half gross margin as product mix, pricing, and manufacturing costs change.
- Monitor remaining convertible-note obligations, dilution from warrants and equity awards, and the February 2014 maturity of the remaining 2014 notes.
- Reconcile future operating results excluding or including unusual charges for IPR&D impairment, tender-offer costs, restructuring, relocation, legal accruals, and acquisition-related fair-value adjustments.
- Review subsequent filings for developments in litigation, Roche-related shareholder claims, restructuring obligations, and contingent acquisition payments.